search
Back to results

Treatment of Chronic Pelvic Pain Due to Endometriosis by Transcutaneous Auricular Vagus Nerve Stimulation (Stim-Endom)

Primary Purpose

Endometriosis

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Transcutaneous Auricular Vagus Nerve Stimulation
Sponsored by
Hopital Foch
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Endometriosis focused on measuring Chronic pelvic pain, Transcutaneous Auricular Vagus Nerve Stimulation

Eligibility Criteria

15 Years - undefined (Child, Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women aged >= 15 years
  • With chronic pelvic pain and/ or dysmenorrhoea and/ or dyspareunia
  • Who has been cared for by a gynecologist in one of the institutions participating in the study
  • Diagnosed with endometriosis
  • Having signed an informed written consent
  • Affiliated to a health insurance scheme

Exclusion Criteria:

  • contraindication to the use of transcutaneous auricular vagus nerve stimulation (cardiac pathology, asthmatic patient)
  • pregnant or breastfeeding women
  • patient undergoing in vitro fertilization
  • associated pathology requiring long-term analgesic treatment
  • patient with atria trans vagal neurostimulation in the 12 months prior to inclusion
  • patient deprived of liberty or under guardianship

Sites / Locations

  • CHI Poissy-St-Germain
  • Hopital FochRecruiting
  • Hopital Saint Joseph

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Transcutaneous auricular vagus nerve stimulation

Standard treatment

Arm Description

A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus. Standard treatment will be continued by the patients of this arm.

Patients of this arm will continue their standard treatment.

Outcomes

Primary Outcome Measures

Change of symptoms related to the pelvic pain
Self assessement of change using Patient's Global Impression of Change (PGIC) scale in which patients rate the improvement of their symptoms related to their pelvic pain from "No change or it get worse" to "A great deal better, and a considerable improvement that has made all the difference" . A favorable result will be "Better, and a definite improvement that has made a real and worthwhile difference" or "A great deal better, and a considerable improvement that has made all the difference"

Secondary Outcome Measures

Efficacy on pain
Self assessement of pain using Endometriosis-associated pelvic pain scale on which patients rate their current pain intensity from 0 "No pain" to 10 "worst possible pain"
Efficacy on severity of patient's symptoms
Physician assessement of severity of patient's symptoms using Global Clinical Impressions-Severity scale on which physicians rate the severity of patient's symptoms from "not evaluated" to "Among the sickest patients"
Efficacy on quality of life
Self assessement of quality of life using Endometriosis Health Profile-5
Efficacy on quality of life
Self assessement of quality of life using EQ-5D scale
Efficacy on Anxiety
Self assessement of anxiety using the Hospital Anxiety and Depression scale
Efficacy on gynecological and pelvic pain symptoms
Self assessement of gynecological and pelvic pain symptoms using ENDOL-4D questionnaire
Efficacy on gynecological and pelvic pain symptoms
Self assessement of gynecological and pelvic pain symptoms using KESS questionnaire
General efficacy of the device Transcutaneous Electronic Neuro Stimulation TENS Eco Plus
Self assessement of satisfaction using a satisfaction questionnaire involving satisfaction, adherence to treatment sessions and ease of use of the device
Collection of possible side effects
collection of vagal malaise, nausea and vomiting

Full Information

First Posted
November 13, 2019
Last Updated
February 27, 2023
Sponsor
Hopital Foch
search

1. Study Identification

Unique Protocol Identification Number
NCT04177511
Brief Title
Treatment of Chronic Pelvic Pain Due to Endometriosis by Transcutaneous Auricular Vagus Nerve Stimulation
Acronym
Stim-Endom
Official Title
Treatment of Chronic Pelvic Pain Due to Endometriosis by Transcutaneous Auricular Vagus Nerve Stimulation
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 13, 2021 (Actual)
Primary Completion Date
February 2025 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hopital Foch

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
6-10% of women of childbearing age suffer from endometriosis, which is mainly manifested by dysmenorrhea, non-menstrual pelvic pain and dyspareunia. Several treatment strategies, including surgical ones, are proposed but they are sometimes insufficient because endometriosis-related pain is frequently accompanied by sensitization. Endometriosis surgery, when indicated, is therefore changeably effective, even though the lesions have been completely resected. Patients therefore consult Pain Units seeking for the effective treatment as the pain persist even after surgical management of endometriosis. Vagus nerve stimulation is a non-invasive technique that includes an anti-inflammatory effect and a modulation of neurotransmitter production (adrenaline, norepinephrine; serotonin, acetylcholine). Yuan and Silberstein published a general review on the technique. Migraine and depression are one of the selected indications. In addition, Napadow et al. published favourable results in a short series of patients with chronic pelvic pain. The Investigators of this study have treated some patients with this technique with a result deemed satisfactory which leads to propose a randomized study to confirm this impression.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometriosis
Keywords
Chronic pelvic pain, Transcutaneous Auricular Vagus Nerve Stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
72 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Transcutaneous auricular vagus nerve stimulation
Arm Type
Experimental
Arm Description
A 30-minute session twice a day during 3 months of transcutaneous auricular vagus nerve stimulation using the TENS Eco Plus. Standard treatment will be continued by the patients of this arm.
Arm Title
Standard treatment
Arm Type
No Intervention
Arm Description
Patients of this arm will continue their standard treatment.
Intervention Type
Device
Intervention Name(s)
Transcutaneous Auricular Vagus Nerve Stimulation
Intervention Description
Transcutaneous Auricular Vagus Nerve Stimulation has an eartip connected to an external stimulator. The device used in this study is the TENS Eco Plus commercialized by Schwa Medico and European Compliance (CE) marked. The electrode is positioned in the cymba concha of the left ear.
Primary Outcome Measure Information:
Title
Change of symptoms related to the pelvic pain
Description
Self assessement of change using Patient's Global Impression of Change (PGIC) scale in which patients rate the improvement of their symptoms related to their pelvic pain from "No change or it get worse" to "A great deal better, and a considerable improvement that has made all the difference" . A favorable result will be "Better, and a definite improvement that has made a real and worthwhile difference" or "A great deal better, and a considerable improvement that has made all the difference"
Time Frame
3 months after enrolment
Secondary Outcome Measure Information:
Title
Efficacy on pain
Description
Self assessement of pain using Endometriosis-associated pelvic pain scale on which patients rate their current pain intensity from 0 "No pain" to 10 "worst possible pain"
Time Frame
Day 1 and 3 months after enrolment
Title
Efficacy on severity of patient's symptoms
Description
Physician assessement of severity of patient's symptoms using Global Clinical Impressions-Severity scale on which physicians rate the severity of patient's symptoms from "not evaluated" to "Among the sickest patients"
Time Frame
Day 1 and 3 months after enrolment
Title
Efficacy on quality of life
Description
Self assessement of quality of life using Endometriosis Health Profile-5
Time Frame
Day 1 and 3 months after enrolment
Title
Efficacy on quality of life
Description
Self assessement of quality of life using EQ-5D scale
Time Frame
Day 1 and 3 months after enrolment
Title
Efficacy on Anxiety
Description
Self assessement of anxiety using the Hospital Anxiety and Depression scale
Time Frame
Day 1 and 3 months after enrolment
Title
Efficacy on gynecological and pelvic pain symptoms
Description
Self assessement of gynecological and pelvic pain symptoms using ENDOL-4D questionnaire
Time Frame
Day 1 and 3 months after enrolment
Title
Efficacy on gynecological and pelvic pain symptoms
Description
Self assessement of gynecological and pelvic pain symptoms using KESS questionnaire
Time Frame
D1 and 3 months after enrolment
Title
General efficacy of the device Transcutaneous Electronic Neuro Stimulation TENS Eco Plus
Description
Self assessement of satisfaction using a satisfaction questionnaire involving satisfaction, adherence to treatment sessions and ease of use of the device
Time Frame
3 months after enrolment
Title
Collection of possible side effects
Description
collection of vagal malaise, nausea and vomiting
Time Frame
3 months after Enrolement

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women aged >= 15 years With chronic pelvic pain and/ or dysmenorrhoea and/ or dyspareunia Who has been cared for by a gynecologist in one of the institutions participating in the study Diagnosed with endometriosis Having signed an informed written consent Affiliated to a health insurance scheme Exclusion Criteria: contraindication to the use of transcutaneous auricular vagus nerve stimulation (cardiac pathology, asthmatic patient) pregnant or breastfeeding women patient undergoing in vitro fertilization associated pathology requiring long-term analgesic treatment patient with atria trans vagal neurostimulation in the 12 months prior to inclusion patient deprived of liberty or under guardianship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marie-Christine DJIAN, MD
Phone
0033 1 46 25 19 22
Email
mc.djian@hopital-foch.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-christine DJIAN, MD
Organizational Affiliation
Hopital Foch, Suresnes
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marc FISCHLER, MD PhD
Organizational Affiliation
Hopital Foch, Suresnes
Official's Role
Study Chair
Facility Information:
Facility Name
CHI Poissy-St-Germain
City
Poissy
State/Province
Ile De France
ZIP/Postal Code
78303
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Catherine SCHULZ, MD
Phone
0033 6 89 25 40 76
Email
catherineschulz.tillet@gmail.com
Facility Name
Hopital Foch
City
Suresnes
State/Province
Ile De France
ZIP/Postal Code
92150
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marie-Christine DJIAN, MD
Phone
0033 1 46 25 19 22
Email
mc.djian@hopital-foch.com
Facility Name
Hopital Saint Joseph
City
Paris
ZIP/Postal Code
75014
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marguerite D'USSEL, MD
Email
mdussel@hpsj.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Treatment of Chronic Pelvic Pain Due to Endometriosis by Transcutaneous Auricular Vagus Nerve Stimulation

We'll reach out to this number within 24 hrs